UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 263

Sortiert nach

Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences

British journal of haematology, 2012-10, Vol.159 (2), p.154-163

2012

Link zum Volltext

Verfügbarkeit prüfen

Lenalidomide‐induced tumour flare reaction in mantle cell lymphoma

British journal of haematology, 2010-11, Vol.151 (4), p.410-412

2010

Link zum Volltext

Verfügbarkeit prüfen

Autoimmune haemolytic anaemia associated with mantle cell lymphoma

International journal of hematology, 2010-03, Vol.91 (2), p.322-325

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia

Clinical cancer research, 2020-06, Vol.26 (12), p.2810-2818

2020

Link zum Volltext

Verfügbarkeit prüfen

On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors

Molecular cancer therapeutics, 2020-02, Vol.19 (2), p.468-478

2020

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement – a multi‐centre case series from the United Kingdom

British journal of haematology, 2017-07, Vol.178 (2), p.327-329

2017

Link zum Volltext

Verfügbarkeit prüfen

Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)

Leukemia, 2020-05, Vol.34 (5), p.1458-1461

2020

Link zum Volltext

Verfügbarkeit prüfen

Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059

Blood, 2017-05, Vol.129 (20), p.2808-2810

2017

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib for mantle cell lymphoma

Future oncology (London, England), 2016-02, Vol.12 (4), p.477-491

2016

Link zum Volltext

Verfügbarkeit prüfen

Does transcutaneous electrical nerve stimulation (TENS) alleviate the pain experienced during bone marrow sampling in addition to standard techniques? A randomised, double-blinded, controlled trial

Journal of clinical pathology, 2015-06, Vol.68 (6), p.479-483

2015

Link zum Volltext

Verfügbarkeit prüfen

A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia

Therapeutics and clinical risk management, 2015-01, Vol.11 (default), p.979-990

2015

Link zum Volltext

Verfügbarkeit prüfen

Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma

Journal of clinical oncology, 2009-11, Vol.27 (32), p.e189-e190

2009

Link zum Volltext

Verfügbarkeit prüfen

Indolent mantle-cell lymphoma: immunoglobulin variable region heavy chain sequence analysis reveals evidence of disease 10 years prior to symptomatic clinical presentation

Journal of clinical oncology, 2011-05, Vol.29 (15), p.e437-e439

2011

Link zum Volltext

Verfügbarkeit prüfen

Position paper on imatinib mesylate in chronic myeloid leukaemia

British journal of haematology, 2002-10, Vol.119 (1), p.268-272

2002

Link zum Volltext

Verfügbarkeit prüfen

Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide±rituximab

Leukemia & lymphoma, 2009, Vol.50 (3), p.463-465

2009

Link zum Volltext

Verfügbarkeit prüfen

Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study

Leukemia & lymphoma, 2009-01, Vol.50 (2), p.211-215

2009

Link zum Volltext

Verfügbarkeit prüfen

The simplified mantle cell lymphoma international prognostic index predicts overall survival but not progression-free survival in patients with mantle cell lymphoma treated with fludarabine and cyclophosphamide±rituximab: results of a randomized phase II trial

Leukemia & lymphoma, 2009-01, Vol.50 (10), p.1709-1711

2009

Link zum Volltext

Verfügbarkeit prüfen

Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus

British journal of haematology, 2010-05, Vol.149 (4), p.578-586

2010

Link zum Volltext

Verfügbarkeit prüfen

Physiological doses of cannabinoids do not adversely affect MCL viability

Leukemia & lymphoma, 2007-09, Vol.48 (9), p.1855-1857

2007

Link zum Volltext

Verfügbarkeit prüfen

Cardiac involvement with mycosis fungoides: Could this explain alemtuzumab toxicity?

Leukemia & lymphoma, 2008-01, Vol.49 (10), p.2022-2024

2008

Link zum Volltext

Verfügbarkeit prüfen

Long-term follow-up of patients with mantle cell lymphoma

Leukemia, 2020-05, Vol.34 (5), p.1458

2020

Link zum Volltext

Verfügbarkeit prüfen

A randomised evaluation of low‐dose cytosine arabinoside (ara‐C) plus tosedostat versus low‐dose ara‐C in older patients with acute myeloid leukaemia: results of the LI‐1 trial

British journal of haematology, 2021-07, Vol.194 (2), p.298-308

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 263

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(254)
Mit Volltextzugriff
(227)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(262)
Japanisch
(16)
Polnisch
(1)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(147)
Life Sciences & Biomedicine
(136)
Humans
(125)
Hematology
(99)
Female
(67)
Male
(66)
Aged
(59)
Middle Aged
(59)
Oncology
(46)
Lymphoma, Mantle-Cell - Drug Therapy
(43)
Adult
(42)
Mantle Cell Lymphoma
(40)
Lymphoma
(37)
Treatment Outcome
(37)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(33)
Aged, 80 And Over
(32)
Rituximab
(27)
Lymphoma, Mantle-Cell - Pathology
(26)
Antineoplastic Agents - Therapeutic Use
(25)
Biological And Medical Sciences
(22)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(65)
British Journal Of Haematology
(38)
Leukemia & Lymphoma
(20)
Journal Of Clinical Oncology
(19)
Clinical Lymphoma, Myeloma And Leukemia
(7)
Haematologica
(7)
Leukemia
(6)
The Lancet
(6)
The Lancet Oncology
(5)
The Lancet. Haematology
(4)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences

Lenalidomide‐induced tumour flare reaction in mantle cell lymphoma

Autoimmune haemolytic anaemia associated with mantle cell lymphoma

Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia

On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors

Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement – a multi‐centre case series from the United Kingdom

Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)

Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059

Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma

Ibrutinib for mantle cell lymphoma

Does transcutaneous electrical nerve stimulation (TENS) alleviate the pain experienced during bone marrow sampling in addition to standard techniques? A randomised, double-blinded, controlled trial

A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia

Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma

Indolent mantle-cell lymphoma: immunoglobulin variable region heavy chain sequence analysis reveals evidence of disease 10 years prior to symptomatic clinical presentation

Position paper on imatinib mesylate in chronic myeloid leukaemia

Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide±rituximab

Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study

The simplified mantle cell lymphoma international prognostic index predicts overall survival but not progression-free survival in patients with mantle cell lymphoma treated with fludarabine and cyclophosphamide±rituximab: results of a randomized phase II trial

Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus

Physiological doses of cannabinoids do not adversely affect MCL viability

Cardiac involvement with mycosis fungoides: Could this explain alemtuzumab toxicity?

Long-term follow-up of patients with mantle cell lymphoma

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

A randomised evaluation of low‐dose cytosine arabinoside (ara‐C) plus tosedostat versus low‐dose ara‐C in older patients with acute myeloid leukaemia: results of the LI‐1 trial

Suchergebnisse filtern